Duchenne muscular dystrophy is caused by mutations in the DMD gene, which provides instructions for making a protein called dystrophin. When these mutations prevent the body from producing any functional dystrophin, muscle fibers lose their structural support and break down with every contraction. About one in three cases arise from spontaneous, new mutations, meaning a child can develop the condition even with no family history.
The DMD Gene and Dystrophin
The DMD gene sits on the X chromosome and is one of the largest genes in the human body. Its job is to produce dystrophin, a protein that acts like a shock absorber inside muscle cells. Dystrophin is part of a protein complex that anchors each muscle cell’s internal scaffolding to the supportive network of proteins outside the cell. Think of it as the fasteners holding a tent fabric to its frame: without them, the fabric tears every time the wind blows.
Beyond structural support, the dystrophin complex also plays a role in cell signaling, helping muscle cells send and receive chemical messages that coordinate normal function. When the DMD gene carries a mutation severe enough to eliminate functional dystrophin entirely, the result is Duchenne. Mutations that leave some working dystrophin intact, even at reduced levels, typically cause the milder Becker muscular dystrophy instead. In Becker, dystrophin levels can range from about 10% to 70% of normal depending on which part of the gene is affected. In Duchenne, dystrophin is essentially absent.
How Muscles Break Down Without Dystrophin
Without dystrophin anchoring the cell membrane, the outer layer of each muscle fiber (the sarcolemma) becomes fragile. Every time the muscle contracts and relaxes, that membrane tears. These micro-injuries allow calcium to flood into the cell at abnormally high levels. Calcium is essential for normal muscle contraction in small, controlled amounts, but when it pours in uncontrolled, it activates enzymes that digest the muscle fiber from the inside out.
The body tries to repair this damage. New muscle fibers regenerate to replace the ones that died, and for a while, this cycle of destruction and repair keeps pace. But the replacement fibers lack dystrophin too, so they suffer the same fate. Over time, the muscle’s ability to regenerate falls behind the rate of damage. The dead muscle tissue gets replaced not by new muscle, but by scar tissue (fibrosis) and fat. This fibrofatty infiltration is progressive: it starts in skeletal muscles like those in the legs and hips, and eventually reaches the heart. Research from the Journal of the American Heart Association has documented fatty replacement in both the left and right ventricles of the heart, sometimes appearing even before heart function measurably declines.
This replacement process is why boys with Duchenne gradually lose strength. The muscles that remain are increasingly diluted with non-functional tissue that cannot contract.
X-Linked Inheritance
Duchenne follows an X-linked recessive inheritance pattern. Because boys have one X chromosome and one Y, a single mutated copy of the DMD gene is enough to cause the disease. Girls have two X chromosomes, so a working copy on one X can typically compensate for a mutated copy on the other. This is why Duchenne overwhelmingly affects boys.
A woman who carries one mutated copy is called a carrier. If she has a son, there is a 50% chance he will inherit the affected X chromosome and develop Duchenne. If she has a daughter, there is a 50% chance the daughter will be a carrier herself. Some carriers do experience mild muscle weakness or heart problems, but full Duchenne in girls is extremely rare.
Spontaneous Mutations Are Common
Not every case of Duchenne runs in the family. About one in three cases results from a de novo mutation, a new genetic change that occurred by chance in the egg or in the early embryo. The mother in these cases is not a carrier, and there was no way to predict or prevent the mutation. This is part of what makes Duchenne difficult to anticipate. The DMD gene’s enormous size makes it more vulnerable to random copying errors during cell division than smaller genes.
For the remaining two-thirds of cases, the mutation is inherited from a carrier mother who may have no symptoms and no idea she carries the gene. Genetic testing can identify carrier status, which is why families with one affected child are typically offered testing for other female relatives.
Early Signs and How It’s Detected
Because muscle damage begins at birth, one of the earliest detectable signs is an enzyme called creatine kinase (CK) leaking from damaged muscle fibers into the bloodstream. In boys with Duchenne, CK levels can be 10 to 100 times higher than normal, even before obvious symptoms appear. Newborn screening programs in some regions use CK testing to catch the condition early.
Physical symptoms usually become noticeable between ages 2 and 5. Parents often notice a child has trouble climbing stairs, falls frequently, or uses a distinctive maneuver to stand up from the floor, pushing off the thighs with both hands to compensate for weak hip muscles. A blood test showing dramatically elevated CK leads to genetic testing of the DMD gene, which confirms the diagnosis and identifies the specific mutation. Knowing the exact mutation matters because some newer therapies target particular types of genetic errors.
Why Duchenne Differs From Becker
Both Duchenne and Becker muscular dystrophy stem from mutations in the same gene, but the severity depends on what the mutation does to the dystrophin protein. In Duchenne, the mutation disrupts the gene so completely that no functional dystrophin is produced. Muscle biopsies show absent dystrophin staining. In Becker, the mutation allows a shorter or partially functional version of dystrophin to be made. Even a small amount of working protein provides enough membrane stability to slow the disease course considerably.
This distinction has real consequences for progression. Boys with Duchenne typically need a wheelchair by their early teens, while those with Becker may remain ambulatory into their 20s, 30s, or beyond. The heart and breathing muscles are affected in both conditions, but the timeline is compressed in Duchenne. Understanding which condition a child has, based on whether the mutation eliminates dystrophin or merely reduces it, shapes treatment planning and expectations from the start.